Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab

JAMA Neurology

Volumn 72, Issue 9, 2015, Pages 989-995

  Kim, Su Hyun ^a   Jeong, In Hye ^a   Hyun, Jae Won ^a   Joung, AeRan ^a   Jo, Hyo Jin ^a   Hwang, Sang Hyun ^a   Yun, Sooin ^a   Joo, Jungnam ^a   Kim, Ho Jin ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD27 ANTIGEN; FRAGMENT C GAMMA RECEPTOR 3A; RITUXIMAB; UNCLASSIFIED DRUG; ANTIBODY; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

ADULT; ALLELE; ARTICLE; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FCGR3A GENE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; INDUCTION CHEMOTHERAPY; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MYELOOPTIC NEUROPATHY; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; RELAPSE; RETROSPECTIVE STUDY; THYROID CANCER; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DISABILITY; GENETICS; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; NEUROMYELITIS OPTICA; PHARMACOGENETICS; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIBODIES; AQUAPORIN 4; DISABILITY EVALUATION; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; RETROSPECTIVE STUDIES; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84942237469     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1276     Document Type: Article

References (25)

1. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64(7):1270-1272.
2. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
3. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412-1420.
4. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-1315.
5. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJA. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-1117.
6. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci. 2007;28(4):209-211.
7. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Variable results after rituximab in neuromyelitis optica. J Neurol Sci. 2012;317(1-2): 103-105.
8. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225-1230.
9. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci. 2013;324(1-2):38-39.
10. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81(8):710-713.
11. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64(13):4664-4669.
12. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res.2006;12(13): 4027-4035.
13. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48(12):673-683.
14. Cornec D, Tempescul A, Querellou S, et al. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol. 2012;91(5):715-721.
15. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725.
16. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940-3947.
17. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758.
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
19. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9): 805-815.
20. Joo J, Kwak M, Chen Z, Zheng G. Efficiency robust statistics for genetic linkage and association studies under genetic model uncertainty. Stat Med. 2010;29(1):158-180.
21. Ogdie A, Haynes K, Troxel AB, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.Ann Rheum Dis. 2014;73(1):149-153.
22. Quartuccio L, Fabris M, Pontarini E, et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis. 2014;73(4):716-721.
23. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V/V and V/F polymorphism. Blood. 2007;110(7):2561-2564.
24. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108(8):2720-2725.
25. Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2012;71(6):875-877.